



Important Safety Information

In clinical trials, the most common adverse events with OraVerse (phentolamine mesylate) were post procedural pain, injection site pain, increased or decreased heart rate and headache. Following injections of phentolamine in non-dental procedures, substantial decreases in blood pressure have occurred which resulted in heart attacks as well as spasms and blocked blood vessels in the brain. Although such effects are uncommon with OraVerse, you should alert your doctor if you experience an increase in heart rate or abnormal heart rhythm (palpitations), particularly if you have a history of heart disease.

See prescribing information attached.

Folded and glued PI

Can numbness be reversed?

Numbness from a local anesthetic is something most of us are used to at the dentist. But lingering numbness can be limiting, affecting your speech, your smile, and your ability to drink. You may even catch yourself drooling.

OraVerse® is a breakthrough that reverses unwanted lingering numbness after routine dental procedures where a local anesthetic containing a vasoconstrictor was used.

OraVerse is indicated for reversal of the soft-tissue anesthesia, i.e., anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic containing a vasoconstrictor.

OraVerse is not recommended for use in children less than 6 years of age or weighing less than 15 kg (33 lbs).

The most common adverse event with OraVerse greater than the control group was injection site pain (5% vs. 4%).

Ask your dental professional if OraVerse is right for you.

www.OraVerse.com



800-872-8305 septodontusa.com 205 Granite Run Drive Suite 150 Lancaster, PA 17601

Can numbness be reversed?

Ask your dentist.





What is OraVerse®?

OraVerse is the first and only product to rapidly reverse the lingering numbness of the lip and tongue from local dental anesthetic that contains a vasoconstrictor.

OraVerse is administered by your dentist immediately following your procedure to speed up the return of sensation in the soft tissues of the mouth.

OraVerse is not recommended for use in children less than 6 years of age or weighing less than 33 lbs.

Ask your dental professional about OraVerse.




Common side effects

- In clinical trials*, the adverse events of OraVerse were similar to the control group.
- The most common adverse event greater than the control group was injection site pain (5% vs. 4%).
- Refer to the Important Safety Information on the inside panel for more information.

Regain your sensation faster.


OraVerse reverses the unwanted lingering numbness from an anesthetic with a vasoconstrictor.

In clinical trials, the patients were able to regain normal sensation twice as fast vs. control.



Regain your function faster.

The trials also showed that OraVerse patients can smile, speak and drink normally sooner and drooling is minimized.



Minutes to observed recovery of normal function (median)

Is OraVerse right for you?

Take this short quiz and discuss it with your dental professional.

1.	It is important to me to regain feeling in my lips and tongue faster after a dental visit.
	Yes, very importantSomewhatA littleNot at all
2.	Speaking normally as soon as possible after a dental visit is important to me. O Yes, very important O Somewhat O A little O Not at all
3.	Drinking normally as soon as possible after a dental visit is important to me. O Yes, very important O Somewhat O A little O Not at all
4.	It is important to me that drooling stop as soon as possible after a dental visit. O Yes, very important O Somewhat O A little O Not at all
5.	I want to recover from numbness after a dental visit faster. O Yes O No
6.	I want my dental professional to tell me more about OraVerse. Yes No, not at this time
* Hersh EV, Moore PA, Papas AS, and colleagues. Reversal of soft-tissue	

^{*} Hersh EV, Moore PA, Papas AS, and colleagues. Reversal of soft-tissue local anesthesia with phentolamine mesylate in adolescents and adults. JADA 2008;139(8):1080-1093. Copyright ©2008 American Dental Association. All rights reserved. Excerpted by permission.